ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.518,03
-0,44%
S&P 500
5.660,69
0,52%
Dow Jones
40.923,40
1,77%
Euro vs US Dollar
1,0896
-0,03%
Bitcoin
64.714,06
-0,21%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Angiotech Pharmaceuticals - Common Shares (MM) (ANPI)

  7. Angiotech Pharmaceuticals - Common Shares (MM) (ANPI) News

ANPI

Angiotech Pharmaceuticals - Common Shares (MM) (ANPI)

Angiotech Pharmaceuticals - Common Shares (MM)
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ANPI
DatumZeitQuelleÜberschriftSymbolFirma
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
17/02/201015h00PR Newswire (US)Angiotech Pharmaceuticals and partner Athersys announces completion of patient enrollment in phase I study of Multistem(R) in acNASDAQ:ANPIAngiotech Pharmaceuticals - Common Shares (MM)
 Showing the most relevant articles for your search:NASDAQ:ANPI

Kürzlich von Ihnen besucht

USOTC
BNPQY
BNP Paribas (QX)
NYSE
DIS
Walt Disney
CCOM
US100
US Tech 100
DBI
SDXP
SDAX
TG
TUI1
Tui
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
NVDA
NVIDIA
TG
D7G
Nel ASA
TG
LHA
Deutsche Lufthansa
COIN
ETHUSD
Ethereum
TG
NOV
Novo Nordisk
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
COIN
BTCUSD
Bitcoin
FX
EURJPY
Euro vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten